Stemgent has completed the sale of its stem cell reagents and services business to ReproCELL in a cash transaction for approximately $8.5 million.
Stemgent is selling the stem cell reagent and services business in order to focus on expanding its human tissue-based brand, Asterand Biosciences.
Asterand has operated successfully for many years and is a leading global provider of high quality, well characterized human tissue and human tissue-based research services which support drug discovery and development and biomarker development and validation.
Concurrent with the sale, the Company name was changed to Asterand Biosciences, Inc.
For further deal information visit Current Agreements (subscription required)
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity